Anumana’s Pfizer-backed cardiac amyloidosis-spotting AI algorithm nabs FDA breakthrough tag
Related Articles
Anumana, Pfizer collaborate on AI-based detection of cardiovascular disease
NS Medical Devices: The research agreement with Pfizer will aid Anumana to develop an AI-enabled ECG algorithm to help detect patients who may be at risk of cardiac amyloidosis{post_date: F d, Y}
Anumana earns first full FDA clearance for AI to detect low ejection fraction
Fierce Biotech: Two years after its launch as a joint venture between the Mayo Clinic and Nference to develop artificial intelligence algorithms capable of pulling out new insights from routine…{post_date: F d, Y}
J&J Hired Thousands of Data Scientists. Will The Strategy Pay Off?
WSJ: One project—with the Mayo Clinic and a health-technology company called Anumana based in Cambridge, Mass.—aims to speed up diagnosis of high blood pressure in the lungs, or pulmonary hypertension.…{post_date: F d, Y}
Midwest providers eye new financial opportunities
Modern Healthcare: Mayo Clinic announced a new technology platform initiative to deliver the next generation of clinical decision support tools, diagnostic insights and care recommendations to help clinicians make faster…{post_date: F d, Y}